Literature DB >> 29942196

Differentiating Molecular Risk Assessments for Prostate Cancer.

Benjamin Press1, Michael Schulster2, Marc A Bjurlin3.   

Abstract

It is critically important to the evolving goals of prostate biopsy to find clinically significant cancer with lethal potential and avoid detection of indolent disease. Better tests and markers are required for improved detection of clinically significant prostate cancer and avoidance of biopsies in men with indolent disease. Currently, there are myriad alternative prostate cancer risk-assessment tests available derived from serum and urine that are designed to improve the specificity for detection of "significant" prostate cancer. Herein we discuss these tests and their clinical implications.

Entities:  

Keywords:  Biomarkers; PSA; Prostate cancer; Prostate-specific antigen; Screening

Year:  2018        PMID： 29942196      PMCID： PMC6003298          DOI： 10.3909/riu0787

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


  47 in total

1.  Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.

Authors:  Andrew Vickers; Angel Cronin; Monique Roobol; Caroline Savage; Mari Peltola; Kim Pettersson; Peter T Scardino; Fritz Schröder; Hans Lilja
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

2.  Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.

Authors:  Siebren Dijkstra; Tim M Govers; Rianne J Hendriks; Jack A Schalken; Wim Van Criekinge; Leander Van Neste; Janneke P C Grutters; John P Michiel Sedelaar; Inge M van Oort
Journal:  BJU Int       Date:  2017-04-29       Impact factor: 5.588

3.  The prostate health index selectively identifies clinically significant prostate cancer.

Authors:  Stacy Loeb; Martin G Sanda; Dennis L Broyles; Sanghyuk S Shin; Chris H Bangma; John T Wei; Alan W Partin; George G Klee; Kevin M Slawin; Leonard S Marks; Ron H N van Schaik; Daniel W Chan; Lori J Sokoll; Amabelle B Cruz; Isaac A Mizrahi; William J Catalona
Journal:  J Urol       Date:  2014-11-15       Impact factor: 7.450

4.  Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above.

Authors:  Andrew Vickers; Emily A Vertosick; Daniel D Sjoberg; Monique J Roobol; Freddie Hamdy; David Neal; Anders Bjartell; Jonas Hugosson; Jenny L Donovan; Arnauld Villers; Stephen Zappala; Hans Lilja
Journal:  J Urol       Date:  2016-09-28       Impact factor: 7.450

5.  Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen.

Authors:  Theresa Y Chan; Stephen D Mikolajczyk; Kristin Lecksell; Matthew J Shue; Harry G Rittenhouse; Alan W Partin; Jonathan I Epstein
Journal:  Urology       Date:  2003-07       Impact factor: 2.649

6.  Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.

Authors:  Massimo Lazzeri; Alexander Haese; Alexandre de la Taille; Joan Palou Redorta; Thomas McNicholas; Giovanni Lughezzani; Vincenzo Scattoni; Vittorio Bini; Massimo Freschi; Amy Sussman; Bijan Ghaleh; Philippe Le Corvoisier; Josep Alberola Bou; Salvador Esquena Fernández; Markus Graefen; Giorgio Guazzoni
Journal:  Eur Urol       Date:  2013-01-24       Impact factor: 20.096

Review 7.  Prostate cancer overdiagnosis and overtreatment.

Authors:  Laurence Klotz
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-06       Impact factor: 3.243

8.  European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.

Authors:  Robert W Foley; Robert M Maweni; Laura Gorman; Keefe Murphy; Dara J Lundon; Garrett Durkan; Richard Power; Frank O'Brien; Kieran J O'Malley; David J Galvin; T Brendan Murphy; R William Watson
Journal:  BJU Int       Date:  2016-02-29       Impact factor: 5.588

9.  Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.

Authors:  Claire de la Calle; Dattatraya Patil; John T Wei; Douglas S Scherr; Lori Sokoll; Daniel W Chan; Javed Siddiqui; Juan Miguel Mosquera; Mark A Rubin; Martin G Sanda
Journal:  J Urol       Date:  2015-01-28       Impact factor: 7.450

10.  A simple, rapid, low-cost technique for naked-eye detection of urine-isolated TMPRSS2:ERG gene fusion RNA.

Authors:  Kevin M Koo; Eugene J H Wee; Paul N Mainwaring; Matt Trau
Journal:  Sci Rep       Date:  2016-07-29       Impact factor: 4.379
View more
  4 in total

Review 1.  How should radiologists incorporate non-imaging prostate cancer biomarkers into daily practice?

Authors:  Pawel Rajwa; Jamil Syed; Michael S Leapman
Journal:  Abdom Radiol (NY)       Date:  2020-12

Review 2.  Monitoring Therapy Efficiency in Cancer through Extracellular Vesicles.

Authors:  Ines Stevic; Gustav Buescher; Franz Lennard Ricklefs
Journal:  Cells       Date:  2020-01-06       Impact factor: 6.600

3.  Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10 ng/mL.

Authors:  Ronald Tutrone; Michael J Donovan; Phillipp Torkler; Vasisht Tadigotla; Tom McLain; Mikkel Noerholm; Johan Skog; James McKiernan
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-05-07       Impact factor: 5.554

4.  Telomere-based risk models for the early diagnosis of clinically significant prostate cancer.

Authors:  Juan Manuel Rubio Galisteo; Luis Fernández; Enrique Gómez Gómez; Nuria de Pedro; Roque Cano Castiñeira; Ana Blanca Pedregosa; Ipek Guler; Julia Carrasco Valiente; Laura Esteban; Sheila González; Nila Castelló; Lissette Otero; Jorge García; Enrique Segovia; María José Requena Tapia; Pilar Najarro
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-05-04       Impact factor: 5.554
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.